These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 26879272

  • 1. Low c-Met expression levels are prognostic for and predict the benefits of temozolomide chemotherapy in malignant gliomas.
    Li MY, Yang P, Liu YW, Zhang CB, Wang KY, Wang YY, Yao K, Zhang W, Qiu XG, Li WB, Peng XX, Wang YZ, Jiang T.
    Sci Rep; 2016 Feb 16; 6():21141. PubMed ID: 26879272
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Prognostic impact of molecular phenotype in patients with recurrent anaplastic glioma treated with prolonged administration of temozolomide.
    Kong DS, Kim HR, Choi YR, Seol HJ, Lee JI, Nam DH.
    J Clin Neurosci; 2015 Sep 16; 22(9):1425-9. PubMed ID: 26138051
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
    Ishii D, Natsume A, Wakabayashi T, Hatano H, Asano Y, Takeuchi H, Shimato S, Ito M, Fujii M, Yoshida J.
    Neurol Med Chir (Tokyo); 2007 Aug 16; 47(8):341-9; discussion 350. PubMed ID: 17721049
    [Abstract] [Full Text] [Related]

  • 6. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM, Paratore S, Caltabiano R, Palmucci S, Parra HS, Privitera G, Motta F, Lanzafame S, Scaglione G, Longo A, Albanese V, Certo F.
    Neurosurg Focus; 2014 Dec 16; 37(6):E4. PubMed ID: 25434389
    [Abstract] [Full Text] [Related]

  • 7. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
    Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M.
    J Clin Oncol; 2009 Dec 10; 27(35):5874-80. PubMed ID: 19901110
    [Abstract] [Full Text] [Related]

  • 8. Akt and β-catenin contribute to TMZ resistance and EMT of MGMT negative malignant glioma cell line.
    Yi GZ, Liu YW, Xiang W, Wang H, Chen ZY, Xie SD, Qi ST.
    J Neurol Sci; 2016 Aug 15; 367():101-6. PubMed ID: 27423571
    [Abstract] [Full Text] [Related]

  • 9. Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas.
    Ochsenbein AF, Schubert AD, Vassella E, Mariani L.
    J Neurooncol; 2011 Jun 15; 103(2):343-51. PubMed ID: 20857319
    [Abstract] [Full Text] [Related]

  • 10. Effect of IFN-beta on human glioma cell lines with temozolomide resistance.
    Yoshino A, Ogino A, Yachi K, Ohta T, Fukushima T, Watanabe T, Katayama Y, Okamoto Y, Naruse N, Sano E.
    Int J Oncol; 2009 Jul 15; 35(1):139-48. PubMed ID: 19513561
    [Abstract] [Full Text] [Related]

  • 11. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
    Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK.
    Pediatr Blood Cancer; 2007 Apr 15; 48(4):403-7. PubMed ID: 16609952
    [Abstract] [Full Text] [Related]

  • 12. Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas.
    Zhang J, Yang JH, Quan J, Kang X, Wang HJ, Dai PG.
    Tumour Biol; 2016 Oct 15; 37(10):13571-13579. PubMed ID: 27468718
    [Abstract] [Full Text] [Related]

  • 13. Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.
    Gramatzki D, Kickingereder P, Hentschel B, Felsberg J, Herrlinger U, Schackert G, Tonn JC, Westphal M, Sabel M, Schlegel U, Wick W, Pietsch T, Reifenberger G, Loeffler M, Bendszus M, Weller M.
    Neurology; 2017 Apr 11; 88(15):1422-1430. PubMed ID: 28298550
    [Abstract] [Full Text] [Related]

  • 14. MGMT methylation: a marker of response to temozolomide in low-grade gliomas.
    Everhard S, Kaloshi G, Crinière E, Benouaich-Amiel A, Lejeune J, Marie Y, Sanson M, Kujas M, Mokhtari K, Hoang-Xuan K, Delattre JY, Thillet J.
    Ann Neurol; 2006 Dec 11; 60(6):740-3. PubMed ID: 17192931
    [Abstract] [Full Text] [Related]

  • 15. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
    Wick W, Meisner C, Hentschel B, Platten M, Schilling A, Wiestler B, Sabel MC, Koeppen S, Ketter R, Weiler M, Tabatabai G, von Deimling A, Gramatzki D, Westphal M, Schackert G, Loeffler M, Simon M, Reifenberger G, Weller M.
    Neurology; 2013 Oct 22; 81(17):1515-22. PubMed ID: 24068788
    [Abstract] [Full Text] [Related]

  • 16. Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas.
    Yin AA, He YL, Etcheverry A, Liu YH, Aubry M, Barnholtz-Sloan J, Liu BL, Mosser J, Lu ZF, Zhang X.
    Clin Epigenetics; 2019 May 14; 11(1):76. PubMed ID: 31088577
    [Abstract] [Full Text] [Related]

  • 17. The tumoral A genotype of the MGMT rs34180180 single-nucleotide polymorphism in aggressive gliomas is associated with shorter patients' survival.
    Fogli A, Chautard E, Vaurs-Barrière C, Pereira B, Müller-Barthélémy M, Court F, Biau J, Pinto AA, Kémény JL, Khalil T, Karayan-Tapon L, Verrelle P, Costa BM, Arnaud P.
    Carcinogenesis; 2016 Feb 14; 37(2):169-176. PubMed ID: 26717998
    [Abstract] [Full Text] [Related]

  • 18. Careful exclusion of non-neoplastic brain components is required for an appropriate evaluation of O6-methylguanine-DNA methyltransferase status in glioma: relationship between immunohistochemistry and methylation analysis.
    Sasai K, Nodagashira M, Nishihara H, Aoyanagi E, Wang L, Katoh M, Murata J, Ozaki Y, Ito T, Fujimoto S, Kaneko S, Nagashima K, Tanaka S.
    Am J Surg Pathol; 2008 Aug 14; 32(8):1220-7. PubMed ID: 18580490
    [Abstract] [Full Text] [Related]

  • 19. Promoter methylation and expression analysis of MGMT in advanced pediatric brain tumors.
    Sardi I, Cetica V, Massimino M, Buccoliero AM, Giunti L, Genitori L, Aricò M.
    Oncol Rep; 2009 Oct 14; 22(4):773-9. PubMed ID: 19724855
    [Abstract] [Full Text] [Related]

  • 20. Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas.
    Li MY, Wang YY, Cai JQ, Zhang CB, Wang KY, Cheng W, Liu YW, Zhang W, Jiang T.
    PLoS One; 2015 Oct 14; 10(6):e0130872. PubMed ID: 26115094
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.